View:
Download DOC
Download PDF
Download XLS
Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 
Amendment No. 1 to
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  April 7, 2010
 
PHARMATHENE, INC.
(Exact name of registrant as specified in its charter)
 
         
Delaware
  
001-32587
  
20-2726770
(State or other jurisdiction
of incorporation)
  
(Commission
File Number)
  
(IRS Employer
Identification No.)
 
One Park Place, Suite 450, Annapolis, Maryland
  
21401
(Address of principal executive offices)
  
(Zip Code)
 
Registrant’s telephone number including area code: (410) 269-2600
 

(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 
 
 
 
Item 9.01
  
Financial Statements and Exhibits

PharmAthene, Inc. is filing this Amendment No. 1 to its Current Report on Form 8-K, initially filed on April 8, 2010, to attach as an exhibit the opinion of its counsel as to the legality of the securities registered and being issued.

(d) The following exhibits are filed herewith:
 
No.
  
Description
     
1.1
  
Placement Agency Agreement dated as of April 7, 2010 by and among the Company and Roth Capital Partners, LLC*
     
5.1
  
Opinion of Sonnenschein Nath & Rosenthal LLP
     
10.1
  
Form of Securities Purchase Agreement dated as of April 7, 2010 between the Company and the Investor*
     
10.2
  
Form of Warrant*
     
23.1
  
Consent of Sonnenschein Nath & Rosenthal LLP (contained in Exhibit 5.1)
     
99.1
  
Press Release dated April 8, 2010*
     

*   Previously filed.
 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
 
PHARMATHENE, INC.
 (Registrant)
     
Date:  April 12, 2010
By:  
/s/ Charles A. Reinhart III
 
Charles A. Reinhart III
 
Senior Vice President and Chief Financial Officer
   
 



Unassociated Document
 
     
1221 Avenue of the Americas
New York, NY 10020-1089
212.768.6700
212.768.6800 fax
www.sonnenschein.com
       
 
April 13, 2010
 
PharmAthene, Inc.
One Park Place
Suite #450
Annapolis, MD 21401

 
Re:
Sale of Common Stock and Warrants
   
registered pursuant to Registration Statement
   
on Form S-3 (File No. 333-156997)
     
Ladies and Gentlemen:
 
 
In our capacity as counsel to PharmAthene, Inc., a Delaware corporation (the “Company”), we have been asked to render this opinion in connection with a registration statement on Form S-3 (the “Registration Statement”), heretofore filed by the Company with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Act”), and the prospectus supplement filed pursuant to Rule 424(b) under the Act, dated as of April 7, 2010 (the “Prospectus Supplement”), in connection with the registration by the Company of the following securities: (i) 1,666,668 shares (the “Shares”) of common stock, par value $0.0001 per share, of the Company (the “Common Stock”), (ii) 500,000 warrants to purchase Common Stock at an exercise price of $1.89 per share (the “Warrants”) and (iii) 500,000 shares (the “Warrant Shares”) of Common Stock that are issuable upon exercise of the Warrants.
 
We are delivering this opinion to you at your request in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Act.
 
In connection with rendering this opinion, we have examined and are familiar with (i) the Company’s Amended and Restated Certificate of Incorporation, as amended, (ii) the Company’s By-Laws, (iii) the Registration Statement, including the prospectus contained therein, (iv) the Prospectus Supplement (such prospectus and the Prospectus Supplement are collectively referred to herein as the “Prospectus”), (v) corporate proceedings of the Company relating to the Shares, the Warrants and the Warrant Shares, and (vi) such other instruments and documents as we have deemed relevant under the circumstances.
 
In making the aforesaid examinations, we have assumed the genuineness of all signatures and the conformity to original documents of all copies furnished to us as original or photostatic copies. We have also assumed that the corporate records furnished to us by the Company include all corporate proceedings taken by the Company to date.
 
Based upon the foregoing and subject to the assumptions and qualifications set forth herein, we are of the opinion that:
 
1.   The Shares have been duly authorized by the Company and, when issued in accordance with the terms set forth in the Registration Statement and the Prospectus, will be validly issued, fully paid and non-assessable.
 
 
Brussels            Chicago            Dallas            Kansas City            Los Angeles            New York            Phoenix            St. Louis
 
San Francisco            Short Hills, N.J.            Silicon Valley            Washington, D.C.            Zurich
 
 
 
 
PharmAthene, Inc.
April 13, 2010
Page 2
 
 
2.   The Warrant Shares have been duly authorized by the Company and, when issued in accordance with the terms set forth in the Registration Statement and the Prospectus, and paid for in accordance with the terms of the Warrants, will be validly issued, fully paid and non-assessable.
 
3.      The Warrants have been duly authorized by the Company and, when issued in accordance with the terms set forth in the Registration Statement and the Prospectus, will be validly issued.
 
The foregoing opinion is limited to the laws of the United States of America and Delaware corporate law (which includes the Delaware General Corporation Law and applicable provisions of the Delaware constitution, as well as reported judicial opinions interpreting same), and we do not purport to express any opinion on the laws of any other jurisdiction.
 
We hereby consent to the use of our opinion as an exhibit to the Registration Statement and to the reference to this firm and this opinion under the heading “Legal Matters” in the prospectus comprising a part of the Registration Statement and any amendment thereto.  In giving such consent, we do not hereby admit that we come within the category of persons whose consent is required under Section 7 of the Act, or the rules and regulations of the Commission thereunder.
 
Very truly yours,
 

 
/s/ Sonnenschein Nath & Rosenthal LLP
 
SONNENSCHEIN NATH & ROSENTHAL LLP